- Home
- GCBC vs ATAI Comparison
GCBC vs ATAI Comparison
Compare GCBC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCBC
- ATAI
- Stock Information
- Founded
- GCBC 1889
- ATAI 2018
- Country
- GCBC United States
- ATAI Germany
- Employees
- GCBC N/A
- ATAI N/A
- Industry
- GCBC Banks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- GCBC Finance
- ATAI Health Care
- Exchange
- GCBC Nasdaq
- ATAI Nasdaq
- Market Cap
- GCBC 373.9M
- ATAI 444.7M
- IPO Year
- GCBC 1998
- ATAI 2021
- Fundamental
- Price
- GCBC $23.58
- ATAI $2.80
- Analyst Decision
- GCBC
- ATAI Strong Buy
- Analyst Count
- GCBC 0
- ATAI 3
- Target Price
- GCBC N/A
- ATAI $10.50
- AVG Volume (30 Days)
- GCBC 22.6K
- ATAI 4.8M
- Earning Date
- GCBC 07-22-2025
- ATAI 08-12-2025
- Dividend Yield
- GCBC 1.53%
- ATAI N/A
- EPS Growth
- GCBC 16.07
- ATAI N/A
- EPS
- GCBC 1.67
- ATAI N/A
- Revenue
- GCBC $69,414,000.00
- ATAI $1,863,000.00
- Revenue This Year
- GCBC N/A
- ATAI $554.22
- Revenue Next Year
- GCBC N/A
- ATAI N/A
- P/E Ratio
- GCBC $13.31
- ATAI N/A
- Revenue Growth
- GCBC 7.46
- ATAI 572.56
- 52 Week Low
- GCBC $20.00
- ATAI $1.03
- 52 Week High
- GCBC $37.25
- ATAI $2.90
- Technical
- Relative Strength Index (RSI)
- GCBC 58.55
- ATAI 68.31
- Support Level
- GCBC $22.10
- ATAI $2.15
- Resistance Level
- GCBC $23.28
- ATAI $2.29
- Average True Range (ATR)
- GCBC 0.85
- ATAI 0.20
- MACD
- GCBC 0.14
- ATAI 0.03
- Stochastic Oscillator
- GCBC 86.76
- ATAI 83.54
About GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.